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2ABSTRACT
Bile salts, phospholipids, and digestive proteins are amphipathic compounds found naturally in the 
human gastrointestinal system. Therefore, it is important to consider their effects on the 
crystallization kinetics and solution behaviour of drugs intended for oral delivery. Supersaturating 
drug delivery systems that employ high energy solid forms and polymeric additives are often 
hailed as the gold standard for increasing drug concentration in the gastrointestinal system. 
However, the effects of amphiphilic compounds present in the gastrointestinal system on the 
crystallization behaviour of these systems are often overlooked. In this study, the effects of bile 
salts, phospholipids, mixtures of phospholipid and bile salts as well as digestive proteins on the 
crystallization kinetics of the antimicrobial agent clofazimine (CFZ) were evaluated. The 
crystallization inhibitory properties of these gastrointestinal amphiphiles were compared with 
commonly used synthetic polymers, and several of these amphipathic gastrointestinal compounds 
showed promise as crystallization inhibitors of clofazimine hydrochloride during induction time 
experiments. The best crystallization inhibitors from this induction time screening were then 
compared as solid physical mixtures in modified fasted state simulated gastric fluid (m-FaSSGF). 
Here it was found that heterogeneous nucleation of CFZ hydrochloride onto the dissolving surface 
of CFZ solid forms prevented these additives from inhibiting crystallization in this biorelevant 
media. This heterogeneous nucleation of CFZ hydrochloride was monitored in real time, using 
optical microscopic techniques.
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3INTRODUCTION
There is an ever increasing number of poorly water-soluble active pharmaceutical ingredients 
(APIs) coming through the drug development pipelines. This trend toward more hydrophobic drug 
substances has led to greater selectivity and potency of APIs, but at the expense of physiochemical 
properties such as solubility and dissolution rate [1], [2]. These properties, particularly intestinal 
solubility, are strongly correlated with the intestinal absorption of orally deliverable medicines and 
are therefore often the rate-limiting step in the absorption of these APIs. Factors which can impact 
the concentration of an API at the site of drug absorption, in particular, dissolution rate and 
crystallization kinetics can become tuneable parameters when designing oral dosage forms to 
optimize their bioavailability [3]. To improve the bioavailability of hydrophobic APIs, formulation 
scientists have developed various strategies to manipulate solubility in the gastrointestinal system. 
Briefly these include; (i) solubilising strategies (such as formulation with cosolvents and/or 
surfactants as well as inclusion into lipid-based formulations) [4], (ii) partial size reduction 
strategies (such as top down or bottom up manufacture of nanoparticles) [5], [6] and (iii) 
supersaturating drug delivery systems (SDDS), such as amorphous solids, crystalline salts, 
cocrystals, etc. [7]–[11]. Along with concentration in the gastrointestinal system, good 
permeability is a requirement for adequate intestinal absorption. Permeation through the 
gastrointestinal membranes is thought to be improved by increasing the concentration of 
molecularly dissolved drug [12], [13]. Thus formulations that produce supersaturated solutions of 
API have significant potential to enhance oral absorption. 
However, such supersaturated solutions of API are inherently unstable and result in a loss of 
solution concentration through crystallization. Therefore maintaining supersaturation levels of an 
API in the human gastrointestinal system is essential to enhance the permeability of the API. 
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4Crystallization from solution occurs via nucleation (formation of an initial solid) and growth 
(expansion of that solid). Most previous studies have focused on using polymeric additives, such 
as cellulose derivatives, to prolong supersaturation by inhibiting nucleation [14]–[17]. However, 
recently several studies have demonstrated that bile salts can also act as crystallization inhibitors 
for hydrophobic APIs [3], [18]–[21]. A recent systemic study of the effects of bile salts, 
phospholipids, and digestive peptides, on the solution concentration of the antibiotic agent 
clofazimine (CFZ), showed that the presence of these amphipathic compounds has a strong 
influence on solution behaviour i.e. stability and concentration [22]. These findings suggest that 
compounds present in the gastrointestinal system have solubilizing and/or crystallization 
inhibitory potential, which could benefit supersaturating drug delivery systems for hydrophobic 
APIs. In this study, we examined the effects of phospholipids, bile salts and the digestive protein 
pepsin on the crystallization behaviour of CFZ.
CFZ is a weakly basic drug, with a pKa of 8.511 [23]. In its free base form (CFZB), the API is 
practically insoluble in neutral, aqueous media with solubility reported to be < 0.01 mg/L [24]. 
CFZ is marketed as an oily suspension of the free base form of the API, called Lamprene® [25]. 
This formulation is usually administered as 50 mg capsules, which give erratic bioavailability, 45 
– 60 %, following oral administration in the fasted state, although administration with food can 
improve bioavailability by reducing the time to reach peak plasma concentration from 12 h to 8 h 
[25]. The extent to which CFZ dissolves is pH dependent and can be calculated from 
experimentally derived solubility-pH studies [22]. Being weakly basic and ionisable, CFZ readily 
forms pharmaceutical salts with acidic coformers [11]. While CFZB exhibits very poor aqueous 
solubility, salt forms can increase solution concentration in water, and in biorelevant media [11]. 
However, in low pH media, solution concentration and solution stability of the protonated CFZH+ 
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5species is reduced through the common ion effect [22]. The concentrations of CFZ that can be 
reached in biorelevant media are ~30 mg/L for modified- fasted state simulated gastric fluid (m-
FaSSGF - pH 1.6) and ~6 mg/L for modified-fasted state simulated intestinal fluid (m-FaSSIF - 
pH 6.5). However, the solution concentration of CFZ in m-FaSSGF and m-FaSSIF is significantly 
reduced in the absence of the phospholipids, bile salts and the digestive proteins present in these 
buffers. The effect of these amphipathic gastrointestinal compounds on the solution behaviour of 
CFZ is best described in previous studies [22], [26]. Briefly, CFZ molecules are taken up into bile 
salt/phospholipid mixed micelles in m-FaSSIF, thus solubilising the neutral CFZ molecules. While 
in m-FaSSGF, CFZ binds to the digestive enzyme pepsin, which acts as a molecular carrier for the 
API and prevents the precipitation of CFZ hydrochloride from the low pH solution (common ion 
effect) [22], [26]. 
The common ion effect ultimately drives protonated CFZ molecules in solution to crystallization 
as a hydrochloric acid salt, CFZ hydrochloride. This phenomenon is not unique to CFZ, but rather 
the common ion effect is a challenge encountered for many crystalline salt forms of weakly basic 
APIs in low pH environments, where crystallisation occurs as a chloride salt, and for salt forms of 
weakly acidic APIs in high pH environments, where crystallisation occurs as a sodium salt [8], 
[27]–[29]. For example, the weakly basic API promethazine exhibits the common ion effect at low 
pH, resulting in a reduction of solution concentration and crystallization as promethazine 
hydrochloride [30]. Serajuddin et al. reported a similar finding for a sodium salt of an acid drug 
(REV 3164; 7‐chloro‐5‐propyl‐1H,4H‐[1,2,4]triazolo[4,3‐a]quinoxaline‐1,4‐dione), where the 
solubility of the drug in water decreased upon the addition of NaCl [31]. However, the common 
ion effect could potentially be overcome by formulation with a crystallization inhibitor, which 
could slow down the rate of precipitation from solution. 
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6In this study, solid forms of CFZ were expected to dissolve in the low pH gastric environment and 
then precipitate from solution as CFZ hydrochloride, through the common ion effect. CFZ 
hydrochloride does not dissolve to any detectable extent in the presence of chloride ions, even at 
pH values where other salt forms of CFZ display solubility [11]. Such solid-state transformations 
of APIs into less soluble solid forms can compromise solution concentration in vivo and potentially 
bioavailability. The aim of this study was to develop a novel solid dose formulation of a CFZ salt, 
with a crystallization inhibitor, to prolong supersaturation in FaSSGF. A panel of potential 
crystallization inhibitors was screened through crystallization induction time experiments of CFZ 
hydrochloride where supersaturation was induced by increasing chloride concentration in the 
media, to mimic the common ion effect. Potential crystallization inhibitors screened included: the 
synthetic polymers PVP and HPMC, and the gastrointestinal (GI) components; bile acids, sodium 
taurocholate, and porcine bile extract, as well as lecithin (a phospholipid extract) and pepsin (a 
digestive enzyme), Figure 1. The crystallization inhibitory properties of these compounds in 
biorelevant dissolution media were then examined as solid physical mixtures with CFZB and CFZ 
phosphate. 
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7Figure 1: Chemical structure of compounds involving in induction time experiments. Chemical structures of CFZB, 
CFZ hydrochloride, and CFZ phosphate are shown. *Porcine bile extract is primarily composed of glycine or taurine 
conjugates of hyodeoxycholic acid, but also contains various bile salts.
Page 8 of 33
ACS Paragon Plus Environment
Crystal Growth & Design
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8MATERIALS AND METHODS:
Materials. Clofazimine (FI, triclinic polymorph, Cambridge Crystallographic Data Centre Ref 
code: CCDC 1135856) was purchased from Beijing Mesochem Technology Co., Ltd. 
Hydrochloric acid, orthophosphoric acid, methanol, tetrahydrofuran (THF),  L- α – 
phosphatidylcholine (lecithin, from egg yolk), pepsin (from porcine gastric mucosa) were obtained 
from Sigma Aldrich (Ireland). Sodium chloride and sodium taurocholate hydrate (NaTc) were 
obtained from Fisher Scientific (Ireland). Hydroxypropyl methylcellulose (HPMC, 4000 mPaS, 
Harke Pharma) and polyvinylpyrrolidone K 30 (PVP, average Mw 40,000, Sigma Aldrich) were 
used as received from suppliers. 
Methods.
Preparation of clofazimine salts. CFZ salts were prepared by recrystallization of CFZ and 
coformer in a 1:1 molar ratio from methanol, as previously reported [11], [22]. 
Solubility of clofazimine hydrochloride. The experimental setup for the solubility measurements 
consisted of a thermostatic water bath, equipped with a cooling unit, a magnetic stir plate and a 
submersible water pump to enhance circulation in the bath. An excess of clofazimine 
hydrochloride was added to solutions of water or water with additives dissolved to 0.005 %. These 
additives included NaTc, PBE, lecithin, PBE and lecithin (4:1), NaTc and lecithin (4:1), PVP, 
HPMC and pepsin (0.1 mg/mL rather than 0.005 %). These suspensions were then placed in the 
water bath at 37℃ and stirred at 400 rpm for 24h. Following this, the solutions were filtered (using 
preheated syringes and syringe filters) and appropriately diluted for solubility measurement on a 
UV-vis spectrophotometer. All solubility measurements were carried out in triplicate.
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9Measurement of crystallisation induction times. Experimental induction time, tind, is defined as 
the sum of the time taken for a critical nuclei formation to occur (true nucleation time, tn) and the 
time is taken for nuclei to grow to a detectable size, tg [32].
𝑡𝑖𝑛𝑑 = 𝑡𝑛 + 𝑡𝑔 (1)
Undersaturated solutions of CFZH+ (40 mg/L) were prepared by dissolving CFZ hydrochloride, 
(Cambridge Crystallographic Data Centre Ref code: CCDC 1053718),  or CFZ phosphate, 
(Cambridge Crystallographic Data Centre Ref code: CCDC 1559558),  in water or in the presence 
of additives (0.005 % of either NaTc, PBE, lecithin, PBE and lecithin (4:1), NaTc and lecithin 
(4:1), PVP and HPMC or 0.1 mg/mL solutions of pepsin) in 250 mL Duran flasks, using ultra-pure 
(Milli-Q) water. These solutions were prepared at 37℃ on a submersible magnetic stir plate at 400 
rpm using PTFE coated magnetic stir bars (Bath A). 200 mL of this stock solution was filtered into 
10 x 20 mL glass vials using either a PTFE or cellulose acetate syringe filter (25 mm, 0.2 µM). A 
magnetic stir bar was added to each vial before capping with a plastic screw cap, lined with PTFE. 
Vials, stir bars, screw caps, syringes, needles and syringe filters were preheated to 50℃ prior to 
filtration. Solutions were then subjected to a second equilibrium period of 1 h at 60℃ (Bath B); 
before crystallization experiments were conducted (solutions containing pepsin were stirred at 
40℃ due to the thermal instability of the protein). Following the second equilibrium period, vials 
were transferred to a third water bath (Bath C) which was set to 37℃ and 800 rpm. Once added to 
Bath C, 0.5 mL of each solution was discarded, leaving a volume of 19.5 mL in each vial. 
Supersaturation was generated by pipetting 0.5 mL of 1 M NaCl (heated to 37℃) into each vial 
containing 19.5 mL of the stock solution while stirring at 800 rpm (resulting in a final 
concentration of NaCl of 25 mM). Crystallisation was detected using a high definition camcorder 
(Sony HDRXR520VE), similar to that reported previously by Mealey et al [33]. Bath C was fitted 
with a strip of white ultra-bright LED lights (12V IP65 Waterproof, Qbspring) to increase contrast 
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10
and aid in the detection of crystals and the 10 vials were positioned directly in front of the light 
strip. Once nucleation occurred, a cloudy purple/black residue was observed in the solution along 
with a loss of the characteristic red colour of the CFZH+ solution species. Soon after nucleation, 
the solution in the vial would become completely colourless, Scheme 1. This process was repeated 
with a fresh stock solution in each case, giving a total of 20 data points for each additive 
investigated during induction time experiments.
Data Analysis for induction time experiments. Where necessary, differences in the average 
induction time data were compared by means of a t-test. A one-way between-subjects ANOVA 
test was conducted using OriginPro 8 SR1 and the ANOVA statistical analysis package to compare 
the data (Tukey HSD test). Differences were considered significant at the 0.05 level.  
Preparation of m-FaSSGF for dissolution experiments. 
Modified FaSSGF was prepared consisting of pepsin (0.1 mg/mL), sodium taurocholate (80 µM), 
lecithin (20 µM), sodium chloride (7.2 mM) and hydrochloric acid (25 mM), as previously 
published [11], [22]. Due to the instability of the protein, pepsin was only added to the solution 30 
mins before dissolution experiments began. 
Dissolution experiments of CFZ solid forms and potential crystallisation inhibitors as 
physical mixtures. Dissolution experiments were conducted in 100 mL Duran flasks containing 
PTFE stir bars and 100 mL of m-FaSSGF. Solutions were stirred at 150 rpm on a submersible stir 
plate in a water bath at 37℃. An excess of a CFZ solid form (20mg, particle size distribution of 63 
- 90 microns) and 5 mg of either NaTc, PBE, PBE and lecithin (4:1), NaTc and lecithin (4:1), or 
HPMC was added to the dissolution medium and the flask was inverted several times. Samples 
were then withdrawn at predetermined time intervals using preheated (40 ℃) 5 mL syringes and 
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hypodermic needles and then filtered using preheated (40 ℃) PTFE or cellulose acetate syringe 
filters (0.2 microns, 25 mm diameter, Fisher Scientific). CFZ concentration was then immediately 
determined using a double beam UV-vis spectrophotometer (Shimadzu, UV-1800) at a detection 
wavelength of 488 nm.
Growing CFZB single crystals for optical microscopy experiments. Single crystals of CFZ F I 
were grown in THF by solvent evaporation crystallization. Saturated solutions of CFZ F I in THF 
were prepared at 37℃ in 20 mL glass vials containing an excess of solute (FI) and agitated at 800 
rpm over a 24 h period. These saturated solutions were then filtered using preheated PTFE syringe 
filters (25 mm, 0.2 µM) into clean, preheated vials. The solution was allowed to cool at to room 
temperature and the top of the vial was covered with aluminium foil into which several pin holes 
were made. Single crystals were harvested after cooling and evaporation of one week. 
Optical microscopy experiments to monitor solution-mediated transformation of CFZB into 
CFZHCl. An inverted light optical microscope (Olympus IX53) integrated with Olympus SC100 
camera combined with a PC with image/video capture using Olympus Stream Essentials software was 
used to monitor the transformation of CFZ F I (CFZB) into CFZ hydrochloride. Briefly single crystals 
of CFZ F I were placed on a glass slide.  A drop of 25 mM HCl was added onto the single crystal using 
a 10 µL micropipette. Micrographs were then obtained at various time points following the addition of 
the HCl to monitor the transformation.
Slurry experiments to monitor solution-mediated transformation of CFZB into CFZHCl. 50 
mg of CFZ F I was added into 20 mL of 25 mM HCl in 25 mL glass vials. These vials contained 
PTFE magnetic stir bars and were placed on a submersible magnetic stirring in a temperature 
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controlled water bath at 37℃ and 400 rpm. Samples were removed, filtered and characterized via 
either SEM or PXRD at various time points.
Scanning electron microscopy (SEM). SEM imaging was performed using a JEOL CarryScope 
scanning electron microscope JCM-5700. Samples were mounted on aluminium stubs with carbon 
tape tabs and coated by an ultrathin gold layer prior to analysis, using a gold sputterer (EMITECH 
K55) and the particles were imaged at a voltage of 5 kV.
Powder X-ray Diffraction (PXRD). Reflection PXRD was performed using an Empyrean 
diffractometer (PANalytical, Phillips) with Cu Kα1,2 radiation (γ = 1.5406 Å) operating at 40 kV 
and 40 mA and at room temperature. Samples were scanned from 4º to 35º (2θ) with 0.0131º (2θ) 
step size and 48.195 seconds per step, on a flat stage that was spinning at 4 rpm. 
RESULTS AND DISCUSSION:
The common ion effect is a problem for poorly soluble ionisable APIs because where these API 
form sodium or chloride salts, the common ion effect causes them to crystallize out of solution in 
the presence of Cl- and Na+ ions [8], [31], [34]–[36]. The resulting chloride or sodium salt forms 
of the drug are practically insoluble in solutions that contain their respective counterions. This is 
a problem for oral delivery, as the gastrointestinal system has a high NaCl concentration. 
Furthermore, if alternative salt forms of these APIs are prepared, they will dissolve in the presence 
of these chloride or sodium ions, only to rapidly crystallize out of solution as the poorly soluble 
sodium or chloride salt forms. The common ion effect for CFZ in biorelevant media was previously 
highlighted in a recently published study by our group [11]. In this study, several salt forms of 
CFZ were prepared, of which CFZ phosphate showed the greatest improvement in solution 
behaviour but as described above, in FaSSGF, it crystallized from solution as CFZ hydrochloride.
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13
Solution Mediated Transformation of CFZB (F I) into CFZ hydrochloride. When an excess 
of CFZB or any salt form of CFZ is added to low pH chloride media, e.g. FaSSGF, the residual 
solid remaining after the dissolution experiments is primarily the CFZ hydrochloride salt [11], 
[24]. This crystallization of CFZ from solution is driven by the common ion effect and results in 
the eventual conversion of the entire solid administered into CFZ hydrochloride. This solution-
mediated transformation was monitored here over time by adding CFZB to 25 mM HCl and 
removing solid samples at various time points for analysis via PXRD, Figure 2. From this 
diffractogram, it can be seen that the characteristic peaks of CFZB lose intensity as the slurry 
experiment continues. This loss of the CFZB form occurs simultaneously with the formation and 
growth of CFZ hydrochloride peaks, with pure CFZ hydrochloride removed from the slurry 
following 24 h. 
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14
Figure 2: Solution mediated transformation of CFZB (F I) into CFZ hydrochloride. Comparison of the PXRD patterns 
obtained from samples of CFZB (FI) in 25 mM HCl at the various ageing time, with pure CFZB (FI) and the CFZ 
hydrochloride salt.
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15
Screening the impact of polymers, bile salts and pepsin on the crystallization of CFZ 
hydrochloride in conditions of high chloride concentration. The driving force for the common 
ion effect for weakly basic ionisable APIs is an increase in counterion concentration, which shifts 
the solubility equilibrium of the dissociated reaction to favour crystallization of the solid salt form 
of the API. The use of synthetic polymers, and recently of bile salts, to inhibit the crystallization 
of hydrophobic APIs is well described in the literature [3], [14]–[17], [21], [37], [38]. Induction 
time experiments were employed here to identify compounds which could slow down this 
crystallization of CFZ hydrochloride from solution. The panel of potential crystallization inhibitors 
screened included PVP and HPMC, lecithin, NaTc, porcine bile extract and porcine pepsin, Figure 
1. To mimic the common ion effect observed in the human gastric system, supersaturation was 
generated by titrating NaCl into aqueous solutions of CFZ hydrochloride, to a final sodium 
chloride concentration of 25 mM (Scheme 1). As previously mentioned CFZ hydrochloride does 
not dissolve to any detectable extent in 25 mM NaCl (detection limit 0.1 mg/L), thus traditional 
supersaturation ratios were not employed in this study. However, the level of supersaturation was 
maintained in the presence of the different additives, as the thermodynamic solubility of CFZHCl 
remained unchanged in the presence of 0.005 % additives (0.1 mg/mL for pepsin) compared to 
CFZHCl in deionised water only (supplementary information), the concentration of CFZH+ in 
solution at the beginning of the induction time experiments was always 40 mg/L and the amount 
of NaCl used to generate supersaturation remained constant.
During these experiments, induction times were detected by a loss of the characteristic deep red 
colour of aqueous solutions of CFZH+. Following crystallization of CFZ hydrochloride, the 
solution begins to lose colour, turning a pale cloudy pink, with specks of black CFZ hydrochloride 
salt forming in the solution, Scheme 1. The resulting induction time plots obtained for CFZ 
hydrochloride in the presence of these compounds are compared in Figure 3. 
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Scheme 1: Summary of induction time procedure; (1) Undersaturated solutions of CFZ solid forms (CFZ 
hydrochloride or CFZ phosphate) were prepared in the presence or absence of potential crystallization inhibitors; (2) 
0.5 mL of 0.1 M NaCl was titrated into these solutions to induce supersaturation through the common ion effect; (3) 
these vials were stirred in front of a high definition camcorder to detect the time of crystal formation (induction time).
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Figure 3: Summary of the induction time studies carried out for CFZ hydrochloride in the presence or absence of 
potential crystallization inhibitors. (a) % of solutions crystallized plotted versus induction time (log scale) and (b) 
average induction times compared as a bar chart.
The potential crystallization inhibitors screened here (Figure 1), had varying effects on the 
induction times of CFZ hydrochloride, Figure 3. In the presence of NaTc, PBE, NaTc and lecithin 
(4:1), PBE and lecithin (4:1) or HPMC, the average induction time of CFZ hydrochloride was 
 (a)
 (b)
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increased from 53 ± 16 s (in the absence of inhibitors) to values of 309 ± 87  s, 666 ± 246 s, 190 ± 
75 s, 423 ± 156 s and 1955 ± 896 s respectively, Figure 3b. This indicates that, in the presence of 
these additives, the crystallization of CFZ hydrochloride from solution was slowed down. 
Conversely, in the presence of lecithin, PVP and pepsin, changes in the average induction time 
were not as obvious, with average induction times of 82.68 ± 31 s, 65 ± 25 s and 92 ± 36 s afforded 
respectively. Due to the partial overlap of these induction time plots (Figure 3a) and considering 
the stochastic nature of nucleation, statistical analysis was used to compare these average induction 
times. Here a significant difference in the presence of lecithin as well as in the presence of pepsin 
was observed at the p < 0.05 level, Supplementary Information. However, in the presence of 
PVP, there was no significant difference in average induction time compared to in its absence, 
Supplementary Information. This indicates that PVP does not have any effect of the 
crystallization of CFZ hydrochloride. The ability of the compounds screened here to inhibit the 
crystallisation of CFZ hydrochloride from solution followed the order: HPMC > PBE > PBE + 
lecithin > NaTc > NaTc + lecithin > pepsin > lecithin > PVP. Interestingly, each of the components 
of FaSSGF has an effect on the crystallization of CFZ hydrochloride from chlorine-rich media. 
This complements our previous study which shows how solution concentration and stability of 
CFZH+ at pH 1.6 (in 25 mM HCl) depends on the presence and concentration of NaTc, lecithin, 
and pepsin in the system [22]. These results explain that the underlying mechanism for this 
manipulation of solution behaviour was through interference with the crystallization kinetics of 
CFZ hydrochloride from these solutions, with the exception of pepsin. The interference of pepsin 
with the crystallization of CFZ is more likely through a protein-drug binding interaction, which is 
discussed in a previous study [26].
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The observation that NaTc and porcine bile extract (a mixture of bile salts) can prolong the 
supersaturation of CFZH+, also correlates well with previous studies conducted by Chen et al., Li 
et al. and Lu et al. [3], [18]–[21], which showed how the crystallization of hydrophobic drugs can 
be slowed and in some cases prevented by the presence of NaTc and other bile acids [3], [18]–
[21]. The enhanced induction time observed here in the presence of the bile salt mixture, PBE, 
compared to NaTc alone (Figure 3b) is consistent with a study by Lu et al., where it was noted 
that mixtures of different bile salts, namely cholate and deoxycholate, were more effective at 
preventing crystallization from solution compared to a solution of only taurocholate [21]. 
Likewise, Lu et al. observed that mixtures of bile salts and lecithin (either cholate and deoxycholate 
with lecithin, or cholate and chenodeoxycholate with lecithin or FaSSIF), showed a lower ability 
to prevent the nucleation of supersaturated solutions of telaprevir compared to systems with single 
bile salt or mixtures of bile present [21]. Here it was also observed that the solutions of a single 
bile salt (NaTc) are better at inhibiting the crystallization of CFZ hydrochloride compared to the 
combination of lecithin and NaTc (Figure 3b). A mixture of bile salts (PBE) is better at inhibiting 
the crystallization of CFZ hydrochloride compared to NaTc alone (Figure 3b) but similar to NaTc 
alone, the ability of PBE to inhibit nucleation is diminished in the presence of phospholipids 
(Figure 3b). In general, in the literature, bile salts are reportedly able to prolong the lifetime of 
supersaturated solutions of hydrophobic drugs, and this ability is somewhat diminished in the 
presence of phospholipids, through the formation of mixed micelles in situ. Thus, the presence of 
phospholipids in the gastrointestinal system, and their prevalence to form mixed micelles with bile 
salts may limit the effectiveness of bile salt based crystallization inhibitors for supersaturating drug 
delivery systems in vivo.  
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Dissolution experiments of CFZ solid forms and potential crystallization inhibitors as 
physical mixtures in m-FaSSGF. The most promising crystallization inhibitors from the 
induction time screening (NaTc, PBE, NaTc + lecithin, PBE + lecithin and HPMC), were then 
analyzed as physical mixtures with the solid forms CFZB or CFZ phosphate in m-FaSSGF, to 
assess their effectiveness as solid dosage forms. From the resulting dissolution profiles 
(Supplementary Information), values for the initial dissolution rate (Dinitial), area under the curve 
(AUC) and maximum solution concentration (Cmax) were obtained, Figure 4. No improvement in 
Cmax was observed in the presence of any of the compounds added as physical mixtures, compared 
with the respective CFZ solid forms alone Figure 4a. However, AUC was marginally increased 
for CFZB in the presence of HPMC and for CFZ phosphate in the presence of PBE and lecithin 
(4:1), Figure 4b. This marginal increase in AUC is likely a result of the crystallization inhibitory 
properties of these compounds identified during induction time screening, Figure 3. For CFZB, 
Dinitial also remained largely unchanged, with a small increase in the presence of the additive of 
NaTc and lecithin (4:1), Figure 4c. For the faster dissolving phosphate salt, the addition of any of 
these additives significantly reduced Dinitial in m-FaSSGF, Figure 4c. 
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Figure 4: Summary of the solution behaviour of CFZB and CFZ phosphate in m-FaSSGF as solid physical mixtures 
with crystallization inhibitors. (a) impact on maximum solution concentration (Cmax); (b) impact on area under the 
curve (AUC); (c) impact on initial dissolution rate (Dinitial).
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Monitoring of the heterogeneous nucleation of CFZ hydrochloride onto the dissolving 
surface of CFZB. Given that NaTc, PBE, NaTc + lecithin, PBE + lecithin and HPMC each 
prevented the crystallization of CFZ hydrochloride during the induction time studies (Figure 3), 
an improvement in solution behaviour was expected during the dissolution experiments of their 
physical mixtures. However, this was not observed, and none of the potential crystallization 
inhibitors provided a significant advantage as physical mixtures in m-FaSSGF compared to the 
respective solid forms of CFZ administered alone, (Supplementary Information). Upon further 
analysis, it became clear that the cause of this failure as physical mixtures was the result of a 
solution mediated solid-state transformation into the CFZ hydrochloride salt. When particles of 
CFZB were removed from solution at the end of dissolution experiments they were found to have 
a black colour, typical of the CFZ hydrochloride salt, while the inside of these black particles 
retained the bright red colour, characteristic of CFZB, Supplementary Information. This 
solution-mediated transformation of CFZB into CFZ hydrochloride was further investigated using 
SEM and optical microscopy techniques. CFZB and CFZ hydrochloride crystals are easily 
distinguishable by their respective morphologies using SEM. CFZB can be seen to have a flat 
block-like morphology, while the CFZ hydrochloride salt has a characteristic a thin flake-like 
morphology, Figure 5. When CFZB was added to 25 mM HCl, shaken for 15 mins, filtered and 
dried, the resulting dried crystals showed evidence of CFZB converting into CFZ hydrochloride 
through heterogeneous nucleation of CFZ hydrochloride occurring on the surface of the free base, 
Figure 5. 
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Figure 5: SEM images obtained from samples of CFZB extracted from 25 mM HCl, showing the conversation of 
CFZB into CFZ hydrochloride occurring on the surface. Pure CFZ hydrochloride is shown for reference.
Highlighted by a red border in Figure 5 is a region of the CFZB crystal, where circular 
arrangements of CFZ hydrochloride crystals have nucleated onto the surface of the free base. As 
CFZB dissolved in 25 mM HCl, the surface of the dissolving crystals appears to provide a template 
onto which the HCl salt can nucleate and grow. From these initial nucleation sites, CFZ 
hydrochloride then grows to expand and cover the entire surface of the CFZB crystals.
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Figure 6: Microscopic analysis of CFZB conversion into CFZ hydrochloride; (1) single crystal of CFZB (FI), (2) 25 
mM HCl was dropped onto the CFZB single crystal and (3) conversion into CFZ HCl monitored by the passage of 
polarized light through the crystal.
Following the addition of 25 mM HCl to the surface of the CFZB single crystal, small rough purple 
regions were seen to begin to form on the CFZB surface, Figure 6. These regions slowly grew to 
occupy more of the CFZB surface and within 1 h of exposure to the HCl solution, the entire surface 
of the crystal was coated in CFZ hydrochloride salt, Figure 6. This coating can be seen as a dark 
purple layer, which prevented the passage of light through the crystal. It is assumed that the 25 
mM HCl added to the surface of CFZB dissolves a layer of CFZB. The high chloride concentration 
of the 25 mM HCl solution then provides a high driving force for CFZH+ in solution to crystallize 
as CFZ hydrochloride. The rough surface of the CFZB created by the dissolving free base provides 
a surface onto which the heterogeneous nucleation can occur. From these initial nucleation sites, 
CFZ hydrochloride expands to cover the entire surface of the CFZB crystal. Eventually, the entire 
sample, not only the surface, will be converted to the CFZ hydrochloride salt as was observed from 
the slurry experiments, Figure 2. The same is true for the solid phosphate salt exposed to 25 mM 
HCl (Supplementary Information). This heterogeneous nucleation of CFZ hydrochloride on 
crystals of CFZB explains why the crystallization inhibitory properties of NaTc, PBE, NaTc + 
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lecithin, PBE + lecithin and HPMC observed during induction time experiments are not seen when 
these compounds were added as physical mixtures. Although these compounds could successfully 
prevent primary nucleation in the induction time experiments, where everything was in solution, 
they appear unable to prevent this heterogeneous nucleation mechanism from occurring. 
The vast majority of publications that deal with the development of supersaturating drug delivery 
systems of BCS class II APIs compare the results of their studies with existing formulations under 
sink conditions, generally to compare dissolution rates. Although the dissolution rates of BCS class 
II compounds are strongly correlated with their absorption rates in the gastrointestinal system, 
many APIs which exhibit poor solubility require high doses of the API. For example, in the case 
of CFZ, 50 mg of the API is administered as an oily emulsion in one dose. Supersaturated solutions 
of API are intrinsically unstable and the presence of some undissolved solid in the gastrointestinal 
system could provide a surface onto which heterogeneous nucleation could occur, thereby limiting 
the effectiveness of such systems. The results of this study would be very different had we chosen 
to compare CFZ salts and crystallization inhibitors under sink conditions, given that the 
crystallization inhibitors identified were able to prevent primary nucleation. This study highlights 
the importance of analysing the solid-state of the formulation during dissolution analysis, to 
uncover possible solid-state transformations or possible heterogeneous nucleation occurring in 
situ.
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CONCLUSIONS
High ion concentrations in the GI tract and the common ion effect are limiting factors for the oral 
delivery of many ionizable drugs which exhibit very poor water solubility. This phenomenon 
ultimately results in a high driving force for the crystallization of an API from solution in either 
low pH or high pH media, depending upon the physiochemical properties of the API. Formulation 
of an API with a crystallization inhibitor should be sufficient to slow desupersaturation and 
temporarily prevent the crystallization of the poorly soluble salt. Such crystallization inhibitors are 
often included in supersaturating drug delivery systems as effective methods of increasing GI 
solubility, and consequently bioavailability, provided that supersaturation is maintained long 
enough for an increase in API absorption across the epithelium cells in the GI tract. In this study 
we have identified several compounds which are able to inhibit the crystallisation of CFZHCl to 
various extents; these include various amphipathic gastrointestinal compounds, such as NaTc, 
PBE, lecithin, pepsin and mixtures of lecithin and bile salts as well as the synthetic polymers 
HPMC and PVP. The ability of these compounds to stabilize supersaturated solutions of CFZ in 
biorelevant media is compromised by heterogeneous nucleation of the poorly soluble salt onto the 
dissolving supersaturating solid form of the API. In m-FaSSGF, a hydrochloric acid salt form of 
CFZ nucleates onto the dissolving solid form, coating the dissolving particles in an insoluble layer 
of the hydrochloric acid salt. Thus of the compounds screened a novel solid dose formulation of a 
CFZ salt, with a crystallization inhibitor, which might prolong supersaturation in FaSSGF was not 
developed. However, this study also demonstrated how components present in the human GI 
system have a natural tendency to impact the crystallisation kinetics and temporarily stabilize 
supersaturated solutions of the hydrophobic drug CFZ. The presence of bile salts and 
phospholipids in the human gastrointestinal system may indeed provide a viable option for 
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crystallisation inhibition in supersaturating drug delivery systems, but in the case of ionisable 
drugs which exhibit poor solubility and are subject to the common ion effect, such as clofazimine, 
solution mediated solid-state transformations can negate the crystallisation inhibition properties of 
additives and/or endogenous components of the GI tract. 
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Overcoming the Common Ion Effect for Weakly Basic Drugs: 
Inhibiting the Crystallization of Clofazimine Hydrochloride in 
Simulated Gastrointestinal Media 
Pauric Bannigan1,2, Vivek Verma1,2, and Sarah P. Hudson1,2*
1Department of Chemical Sciences, University of Limerick, Castletroy, Co. Limerick, Ireland. 
2Synthesis and Solid State Pharmaceutical Centre, Bernal Institute, University of Limerick, 
Castletroy, Co. Limerick, Ireland. 
Synopsis
The presence of crystallisation inhibitors, for example, polymers, bile salts and phospholipids, in 
gastrointestinal media can inhibit crystallisation in supersaturating drug delivery systems. 
However, in the case of ionisable drugs which exhibit poor solubility and are subject to the 
common ion effect, such as clofazimine, solution mediated solid-state transformations can negate 
their crystallisation inhibition properties.
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